<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04820842</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-994-1504</org_study_id>
    <secondary_id>2021-000251-39</secondary_id>
    <nct_id>NCT04820842</nct_id>
  </id_info>
  <brief_title>A Study of TAK-994 in Adults With Narcolepsy</brief_title>
  <official_title>A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adults with narcolepsy who have completed the TAK-994-1501 study will be able to take part in&#xD;
      this study.&#xD;
&#xD;
      The main aim of this study is to check if participants have side effects from TAK-994.&#xD;
&#xD;
      Participants will take one of 3 different TAK-994 dose for 8 weeks.&#xD;
&#xD;
      Then, half the participants will continue with their dose of TAK-994 and half will take a&#xD;
      placebo. In this study, a placebo will look like a TAK-994 tablet but will not have any&#xD;
      medicine in it. Participants will take TAK-994 or placebo for 4 weeks.&#xD;
&#xD;
      Participants will visit the clinic for a final check-up 2 weeks after their last dose of&#xD;
      TAK-994 or placebo.&#xD;
&#xD;
      The study doctors will check for side effects from TAK-994 and placebo throughout the study.&#xD;
&#xD;
      Participants will continue to record any narcolepsy symptoms as they did in Part B of the TAK&#xD;
      994-1501 study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in the study is called TAK-994. TAK-994, is being tested to treat&#xD;
      participants with NT1. Participants who completed Part B of TAK-994-1501(NCT04096560) will be&#xD;
      eligible for enrollment in this study.&#xD;
&#xD;
      This study will enroll approximately 112 patients to receive one of three different TAK 994&#xD;
      dose for 8 weeks (active drug extension period). Participants will be randomly assigned to&#xD;
      one of these different TAK 994 doses which will remain undisclosed to the participant and&#xD;
      study doctor during the study (unless there is an urgent medical need).&#xD;
&#xD;
      Following the 8-week Active Drug Extension Period, participants will continue into a 4-week&#xD;
      Double-blind Randomized Withdrawal Period and will receive TAK-994 or Placebo.&#xD;
&#xD;
      Participants randomized to TAK-994 will continue to receive the same dose as before.&#xD;
&#xD;
      This multi-center trial will be conducted worldwide. The duration of treatment in this study&#xD;
      is 12 weeks plus a 2 week safety follow up period. Participants will visit the clinic 10&#xD;
      times after the first dosing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 30, 2021</start_date>
  <completion_date type="Anticipated">January 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with at Least One Treatment Emergent Adverse Event (TEAE) During the Active Drug Extension Period</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participants administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A TEAE is defined as an AE with an onset that occurs after receiving study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with at Least One Post-dose Markedly Abnormal Value (MAV) in Laboratory Test During the Active Drug Extension Period</measure>
    <time_frame>Baseline up to Week 8</time_frame>
    <description>Markedly abnormal values for laboratory tests (hematology, serum chemistries, and urinalysis) will be collected as per pre-specified criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with at Least One Post-dose MAV for Vital Signs During the Active Drug Extension Period</measure>
    <time_frame>Baseline up to Week 8</time_frame>
    <description>Markedly abnormal values for vital signs (body temperature, heart rate, respiratory rate, sitting blood pressure and pulse) will be collected as per pre-specified criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with at Least One Post-dose MAV for Electrocardiogram (ECG) Parameters During the Active Drug Extension Period</measure>
    <time_frame>Baseline up to Week 8</time_frame>
    <description>A 12 lead ECG will be performed and markedly abnormal values. will be collected as per pre-specified criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with at Least One TEAE During the Randomized Withdrawal Period of the Study</measure>
    <time_frame>Weeks 8 to 14</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a clinical investigation participants administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A TEAE is defined as an AE with an onset that occurs after receiving study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with at Least One Post-dose MAV for Laboratory Test During the Randomized Withdrawal Period</measure>
    <time_frame>Weeks 8 to 14</time_frame>
    <description>Markedly abnormal values for laboratory tests for (hematology, serum chemistries, and urinalysis) will be collected as per pre-specified criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with at Least One Post-dose MAV for Vital Signs During the Randomized Withdrawal Period</measure>
    <time_frame>Weeks 8 to 14</time_frame>
    <description>Markedly abnormal values (body temperature, heart rate, respiratory rate, sitting blood pressure and pulse) will be collected as per pre-specified criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with at Least One Post-dose MAV for ECG Parameters During the Randomized Withdrawal Period</measure>
    <time_frame>Weeks 8 to 12</time_frame>
    <description>A 12 lead ECG will be performed and markedly abnormal values will be collected as per pre-specified criteria.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Narcolepsy Type 1 (NT 1)</condition>
  <arm_group>
    <arm_group_label>Active Drug Extension Period: TAK-994 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-994 dose 1, tablets, orally, from Day 1 (Day 57 of previous study) to Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Drug Extension Period: TAK-994 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-994 dose 2, tablets, orally, from Day 1 (Day 57 of previous study) to Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Drug Extension Period: TAK-994 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-994 dose 3, tablets, orally, from Day 1 (Day 57 of previous study) to Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double-blind Randomized Withdrawal Period: TAK-994 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following the Active Drug Extension Period, participants randomized to active treatment Dose 1 will continue to receive same dose (TAK-994, dose 1, tablets, orally) from Day 57 to Day 84.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double-blind Randomized Withdrawal Period: TAK-994 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following the Active Drug Extension Period, participants randomized to active treatment Dose 2 will continue to receive same dose (TAK-994, dose 2, tablets, orally) from Day 57 to Day 84.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double-blind Randomized Withdrawal Period: TAK-994 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following the Active Drug Extension Period, participants randomized to active treatment Dose 3 will continue to receive same dose (TAK-994, dose 3, tablets, orally) from Day 57 to Day 84.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double-blind Randomized Withdrawal Period: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Following the Active Drug Extension Period participants will receive placebo-matching tablets for 4 weeks (from Day 57 to Day 84).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-994</intervention_name>
    <description>TAK-994 tablets.</description>
    <arm_group_label>Active Drug Extension Period: TAK-994 Dose 1</arm_group_label>
    <arm_group_label>Active Drug Extension Period: TAK-994 Dose 2</arm_group_label>
    <arm_group_label>Active Drug Extension Period: TAK-994 Dose 3</arm_group_label>
    <arm_group_label>Double-blind Randomized Withdrawal Period: TAK-994 Dose 1</arm_group_label>
    <arm_group_label>Double-blind Randomized Withdrawal Period: TAK-994 Dose 2</arm_group_label>
    <arm_group_label>Double-blind Randomized Withdrawal Period: TAK-994 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo-matching tablets.</description>
    <arm_group_label>Double-blind Randomized Withdrawal Period: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Participant with a diagnosis of Narcolepsy Type 1 (NT1) who has completed TAK-994-1501&#xD;
        Part B before enrollment (which will occur immediately following the final TAK-994-1501&#xD;
        assessments), and for whom the investigator has no clinical objection they be enrolled.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Participant has a clinically significant moderate or severe ongoing AE related to the&#xD;
        study drug from the prior study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wright Clinical Research</name>
      <address>
        <city>Alabaster</city>
        <state>Alabama</state>
        <zip>35007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona 300151190</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CITrials - Bellflower</name>
      <address>
        <city>Bellflower</city>
        <state>California</state>
        <zip>90706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Monica Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford School of Medicine</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Research Network, Inc 150118105</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SDS Clinical Trials, Inc.</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alpine Clinical Research Center 1024762</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delta Waves Sleep Disorders and Research Center 300148510</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80918</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Medical Institute</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Medicine Specialists of South Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site Partners, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JSV Clinical Research Study, Inc</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Pulmonary Research Institute, LLC 300127039</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroTrials Research, Inc. 300116336</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Practitioners, LLC Macon</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute 300169881</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hawaii Pacific Neuroscience</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Neurological Center 150711262</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Research Institute, Inc. University of Kansas Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helene A. Emsellem, MD PC trading as &quot;The Center for Sleep &amp; Wake Disorders&quot; 150119420</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center CardioVascular Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Carolina Elite</name>
      <address>
        <city>Denver</city>
        <state>North Carolina</state>
        <zip>28037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Gastonia</name>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <zip>28054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raleigh Neurology Associates 300209729</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raleigh Neurology Associates,300209729</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTI Clinical Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intrepid Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation 100428</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Sleep Medicine and Neuroscience Institute 186</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Respiratory Specialists Berks Schuylkill Respiratory Specialists Ltd</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (MUSC) PARENT</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bogan Sleep Consultants, LLC 150711087</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Therapy &amp; Research Center 300151246</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Sleep Medicine Associates</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Ottawa Sleep Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2A 3Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Sleep Institute</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4P 1P2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jodha Tishon Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 3A3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove Dept of Neurologicka klinika</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze Dept of Neurologicka klinika 1.LF UK a VFN v Praze</name>
      <address>
        <city>Praha 2</city>
        <zip>128 21</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Terveystalo Helsinki Uniklinikka 300186257</name>
      <address>
        <city>Helsinki</city>
        <zip>00380</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Gui de Chauliac Service de Neurologie</name>
      <address>
        <city>Montpellier</city>
        <state>Herault</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Roger Salengro - CHU Lille service de neurologie D</name>
      <address>
        <city>Lille Cedex</city>
        <state>Nord</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SomnoCenter Budapest</name>
      <address>
        <city>Budapest</city>
        <zip>1012</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Oasi Maria SS 300206751</name>
      <address>
        <city>Troina</city>
        <state>Enna</state>
        <zip>94018</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Bologna-Clinica Neurologica-Dipartimento di Scienze Neurologiche</name>
      <address>
        <city>Bologna</city>
        <zip>40123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele (San Raffaele Turro) Clinica Neurologica- Div Malattie del Sonno</name>
      <address>
        <city>Milano</city>
        <zip>20127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico Tor Vergata U.O.C. Neurologia</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SOUSEIKAI PS Clinic Dept of Internal Medicine</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka-Ken</state>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>You Ariyoshi Sleep Clinic Dept of Psychiatry</name>
      <address>
        <city>Kitakyushu-shi</city>
        <state>Fukuoka-Ken</state>
        <zip>802-0084</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital Dept of Neuropsychiatry</name>
      <address>
        <city>Kurume-shi</city>
        <state>Fukuoka-Ken</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiseikai Kita Shin Yokohama Internal Medicine Clinic Dept of Internal Medicine</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa-Ken</state>
        <zip>223-0059</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howakai Kuwamizu Hospital Dept of Internal Medicine</name>
      <address>
        <city>Kumamoto-shi</city>
        <state>Kumamoto-Ken</state>
        <zip>862-0954</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jinyukai Kotorii Isahaya Hospital Dept of Psychiatry</name>
      <address>
        <city>Isahaya-shi</city>
        <state>Nagasaki-Ken</state>
        <zip>854-0081</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shunkaikai Inoue Hospital Dept of Respiratory Medicine</name>
      <address>
        <city>Nagasaki-shi</city>
        <state>Nagasaki-Ken</state>
        <zip>850-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gokeikai Osaka Kaisei Hospital Dept of Sleep Medicine</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka-Fu</state>
        <zip>532-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyowakai Hannan Hospital Dept of Psychiatry</name>
      <address>
        <city>Sakai-shi</city>
        <state>Osaka-Fu</state>
        <zip>599-8263</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koishikawa Tokyo Hospital Dept of Psychiatry</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo-To</state>
        <zip>112-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nihon University Itabashi Hospital Dept of Neuropsychiatry</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo-To</state>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yoyogi Sleep Disorder Center Dept of Psychiatry</name>
      <address>
        <city>Shibuya-ku</city>
        <state>Tokyo-To</state>
        <zip>151-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep Support Clinic Dept of Psychosomatic Medicine/Psychiatry</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo-To</state>
        <zip>140-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep &amp; Stress Clinic Dept of Psychiatry</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo-To</state>
        <zip>141-6003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sumida Hospital Phase I</name>
      <address>
        <city>Sumida-ku</city>
        <state>Tokyo-To</state>
        <zip>130-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, St. Vincent's Hospital 300187879</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggi-do</state>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Hospital 300144594</name>
      <address>
        <city>Daegu</city>
        <zip>42601</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Araba Sede Santiago Sleep Unit</name>
      <address>
        <city>Vitoria</city>
        <state>Alava</state>
        <zip>01004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Castellon Servicio de Neurofisiologia</name>
      <address>
        <city>Castellon de la Plana</city>
        <state>Castellon</state>
        <zip>12004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona Servicio de Neurologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vithas Nuestra Senora de America Neurofisiologia Clinica</name>
      <address>
        <city>Madrid</city>
        <zip>28043</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.takeda.com/study-detail/60659bc6620b3b001e9dbb46</url>
    <description>To obtain more information on the study, click here/on this link</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Narcolepsy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https:// clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/ takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

